You are here: Industry Insights > AdCOVID

News List

Altimmune to discontinue Covid-19 vaccine programme pharmaceutical-technology
June 30, 2021
Altimmune has decided to discontinue the development of its investigational Covid-19 vaccine, AdCOVID, due to lower responses in Phase I clinical trial.
Altimmune, Lonza Expand AdCOVID Manufacturing Pact contractpharma
March 15, 2021
Lonza to commission a dedicated suite for clinical and commercial supply of Altimmune’s COVID-19 vaccine candidate at its Houston facility.
FDA clears Altimmune’s IND application for Covid-19 vaccine candidate trial pharmaceutical-technology
February 19, 2021
The US Food and Drug Administration (FDA) has cleared Altimmune’s Investigational New Drug (IND) application for its Phase I clinical trial of an intranasal Covid-19 vaccine candidate, AdCOVID.
Altimmune submits FDA application for intranasal Covid-19 vaccine candidate pharmaceutical-technology
November 27, 2020
Altimmune has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) to start a Phase I clinical study of its Covid-19 vaccine candidate.
Altimmune Adds Lonza as Mfg. Partner for Supply of AdCOVID contractpharma
November 12, 2020
Single-dose intranasal vaccine for COVID-19 designed to generate a broad immune response with nasal mucosal immunity to prevent infection and transmission.
Altimmune and CDMO Vigene Enter COVID-19 Vax Pact contractpharma
August 04, 2020
Ink manufacturing agreement for AdCOVID single dose intranasal vaccine candidate.
Altimmune partners with DynPort on intranasal Covid-19 vaccine pharmaceutical-technology
July 13, 2020
Biopharmaceutical firm Altimmune has signed a teaming agreement with DynPort Vaccine to support US Government funding efforts for the development of its intranasal Covid-19 vaccine candidate, AdCOVID.